Abalos Therapeutics

Novel Anti-Cancer Aproach

Düsseldorf, Germany · $14.0M raised

Headquarters
Düsseldorf
Business Model
B2B
Total Funding
$14.0M
Last Round
$14.0M Series AOct 2019
Rounds
1

About

Abalos Therapeutics is a clinical-stage biotech developing next-generation cancer immunotherapies through its proprietary AdaptInnate platform, which harnesses arenaviruses to trigger targeted, durable anti-tumor immune responses without destroying host cells. Its lead candidate, ABX-001, entered first-in-human clinical trials for solid tumors in 2025 after showing marked tumor regression and a favorable safety profile in preclinical studies. The company was founded to translate the research of immunologists Karl Lang and Philipp Lang into novel anti-cancer therapies.

Summary

Abalos Therapeutics is a Biotech company based in Düsseldorf, Germany. It has raised $14.0M in total across 1 round, most recently a $14.0M Series A round in Oct 2019. Investors include Boehringer Ingelheim Venture Fund, NRW.BANK and High-Tech Grunderfonds.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AOct 2019
$14.0M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Abalos Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/abalos-therapeutics"><img src="https://indexed.vc/api/badge/company/abalos-therapeutics" alt="Abalos Therapeutics on Indexed.vc" width="260" height="76" /></a>